Breaking Finance News

Corium International Inc (NASDAQ:CORI) has been upgraded to Buy in a statement by WBB Securities earlier today.

Displaying a price of $8.70, Corium International Inc (NASDAQ:CORI) traded 0.00% even on the day. With the last stock price close up 31.23% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.05% over the date range. Corium International Inc has recorded a 50-day average of $8.25 and a two hundred day average of $5.65. 70,903 shares of CORI traded hands, down from an average trading volume of 274,028

WBB Securities has upgraded Corium International Inc (NASDAQ:CORI) to Buy in a statement released on 07/07/2017.

On Tuesday June 06, 2017, Zacks Investment Research released a statement about Corium International Inc (NASDAQ:CORI) upped the target price from $0.00 to $8.50 that suggested an upside of 0.13%.

Recent Performance Chart

Corium International Inc (NASDAQ:CORI)

Corium International Inc has 52 week low of $2.67 and a 52 week high of $9.57 and has a market capitalization of $0.

In addition to WBB Securities reporting its target price, a total of 6 brokers have issued a report on the stock. The consensus target price is $14.67 with zero equity analysts rating the company a strong buy, 0 firms rating the stock a buy, 0 analysts rating the company a hold, zero analysts rating the company a underperform, and lastly 0 brokers rating the stock a sell.

General Information About Corium International Inc (NASDAQ:CORI)

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer's disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *